Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
NCT03281369 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- October 13, 2017
- Completion date
- October 9, 2025
- Enrollment
- 219 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.
gastric adenocarcinoma or gastroesophageal junction adenocarcinoma or esophageal carcinoma